Franck Morschhauser MD, PhD
Tazemetostat, a small molecule that targets epigenetic activity of the EZH2
gene, is being investigated as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). The drug is being administered as monotherapy or in combination with prednisone in a 6-cohort, biomarker-driven phase II trial (NCT01897571).
... to read the full story